Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2021

View Archived Issues

Wuhan LL Science and Technology Development Co. patents P2X4 receptor antagonists

New GTPase KRAS inhibitors discovered at REVOLUTION Medicines

Kyorin Pharmaceutical and collaborators describe protein G9a inhibitors

Sinovent identifies new GTPase KRAS G12C mutant inhibitors

New CDK8 and/or CDK19 inhibitors synthesized at the Dana-Farber Cancer Institute

Karuna reports phase Ib data on KarXT in healthy elderly volunteers

XBiotech initiates trial of XB-2001 with chemotherapy for pancreatic cancer

First-in-human study of BDB-018 explores use in advanced solid tumors

Seal Rock begins phase I trial of SRT-015 for NASH

Titan reports in vivo data on TP-2021 implant in model of chronic pruritus

Mercaptor advances programs in COVID-19 brain inflammation and epilepsy

Study supports miR panel for diagnosing multiple sclerosis

CStone reports data on Gavreto in Chinese patients with advanced RET fusion-positive NSCLC

Fulcrum reports phase IIb data on losmapimod in FSHD

Sellas reports phase I data on galinpepimut-S with nivolumab in malignant pleural mesothelioma

Kaken begins Japanese phase I study of sofpironium bromide gel in primary palmoplantar hyperhidrosis

Back to the basics for new insights, with new technology

Applied Genetic Technologies reports 12-month data from phase I/II achromatopsia trials

Follicum discontinues development of FOL-005 for alopecia

Aravive advances phase Ib evaluation of AVB-500 with cabozantinib in clear cell renal cel carcinoma

Arcus provides interim analysis from ARC-7 study of domvanalimab combinations in NSCLC

Dosing begins in phase II study of ALPN-101 in SLE

First patient enters phase II study of TG-4001 with avelumab in HPV16-positive anogenital tumors

IN3BIO cleared to begin phase I/II trial of IN-01 for colorectal cancer in Bulgaria

Abivax reports phase IIa data on ABX-464 in rheumatoid arthritis

SelectImmune Pharma and Lonza collaborate to develop processes for novel immunotherapy protein NlpD

Carmot opens phase I study of dual GLP-1 and GIP receptor modulator CT-388

Bristol Myers Squibb exercises option to U.S. license for Prothena's PRX-005

4D Molecular Therapeutics reports pipeline update

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...